Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + eribulin + carboplatin in previously treated advanced triple-negative breast cancer
ChiCTR2400082647Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, eribulin and carboplatin in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
sintilimaberibulincarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2400082647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082647.